Physician profile
John Suffredini
NPI 1235591389
$15,494.65
in general payments reported to CMS, 2019-2025
25 companies · $765 in 2025
The $765 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $1,574 · 2021: $2,009 · 2022: $2,245 · 2023: $4,302 · 2024: $3,153 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,434 · Travel and Lodging: $3,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,434.24 |
| Travel and Lodging | $3,786.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,693.01 | 2019-2025 | Supera, Cardiomems, Amplatzer |
| Boston Scientific Corporation | $2,001.32 | 2021-2024 | Rotapro |
| Abiomed | $1,476.23 | 2019-2025 | Impella |
| Cardiovascular Systems INC. | $429.82 | 2019-2023 | Diamondback Coronary |
| Amgen INC. | $293.89 | 2019-2024 | Repatha |
| Inari Medical, INC. | $284.02 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $254.26 | 2019-2021 | |
| Philips North America LLC | $236.97 | 2023-2024 | (Bh4) Igt Devices Undivided |
| Chiesi USA, INC. | $182.86 | 2022-2025 | Kengreal, Cleviprex |
| Elutia, INC. | $167.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $151.29 | 2019-2021 | |
| Shockwave Medical, INC | $148.01 | 2025 | |
| Osprey Medical INC | $144.28 | 2021 | |
| Teleflex LLC | $137.33 | 2024-2025 | Chocolate, Turnpike, Trapliner |
| Medtronic Vascular, INC. | $127.08 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $123.61 | 2022-2024 | |
| Astellas Pharma US INC | $123.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.44 | 2021-2023 | |
| Lundbeck LLC | $110.47 | 2019 | |
| Penumbra, INC. | $96.47 | 2020 | |
| Pfizer INC. | $65.43 | 2019-2021 | |
| Cathworks, INC. | $44.96 | 2022 | |
| Cardiva Medical, INC. | $36.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.65 | 2024 | Jardiance |
| Medtronic, INC. | $23.21 | 2023 | Corevalve Evolut R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Suffredini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.